Thyroid cancer gender disparity
- PMID: 21142662
- PMCID: PMC3077966
- DOI: 10.2217/fon.10.127
Thyroid cancer gender disparity
Abstract
Cancer gender disparity in incidence, disease aggressiveness and prognosis has been observed in a variety of cancers. Thyroid cancer is one of the fastest growing cancer diagnoses worldwide. It is 2.9-times more common in women than men. The less aggressive histologic subtypes of thyroid cancer are more common in women, whereas the more aggressive histologic subtypes have similar gender distribution. The gender disparity in incidence, aggressiveness and prognosis is well established for thyroid cancer but the cause of the disparity is poorly understood. The aim of this article is to evaluate the current evidence on the cause of thyroid cancer gender disparity. Dietary and environmental factors do not appear to have a significant role in thyroid cancer gender disparity. Common somatic mutations in BRAF, rearranged in transformation/papillary thyroid carcinomas (RET/PTC) and neurotrophin receptor-tyrosine kinase (NTRK) also do not account for the gender disparity in thyroid cancer. While reproductive factors would seem a logical hypothesis to account for the gender disparity, there appears to be no conclusive effect on the risk of developing thyroid cancer. Recent studies on estrogen receptor status in thyroid cancer show a difference in the receptor subtypes expressed based on the histology of thyroid cancer. Moreover, the response to estrogen is dependent on the specific estrogen receptor expressed in thyroid cancer cells. However, what determines the tumor-specific sex hormone receptor expression is unclear. No established molecular factors appear to explain gender differences in thyroid cancer. Therefore, the application of high-throughput genomic and proteomic approaches to the study of thyroid cancer gender disparity could be helpful for better understanding the molecular basis for gender differences in thyroid and other cancers.
Conflict of interest statement
The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.
Figures


Similar articles
-
Menstrual and reproductive history and use of exogenous sex hormones and risk of thyroid cancer among women: a meta-analysis of prospective studies.Cancer Causes Control. 2015 Apr;26(4):511-8. doi: 10.1007/s10552-015-0546-z. Epub 2015 Mar 10. Cancer Causes Control. 2015. PMID: 25754110 Review.
-
Multiple genetic alterations in papillary thyroid cancer are associated with younger age at presentation.J Surg Res. 2010 May 15;160(2):179-83. doi: 10.1016/j.jss.2009.05.031. Epub 2009 Jun 17. J Surg Res. 2010. PMID: 19765726
-
RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes.Clin Cancer Res. 1998 Feb;4(2):287-94. Clin Cancer Res. 1998. PMID: 9516913
-
Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.Hum Pathol. 2020 Dec;106:82-92. doi: 10.1016/j.humpath.2020.09.004. Epub 2020 Sep 25. Hum Pathol. 2020. PMID: 32980422
-
RET/PTC rearrangement in thyroid tumors.Endocr Pathol. 2002 Spring;13(1):3-16. doi: 10.1385/ep:13:1:03. Endocr Pathol. 2002. PMID: 12114746 Review.
Cited by
-
Common single nucleotide polymorphisms in genes related to immune function and risk of papillary thyroid cancer.PLoS One. 2013;8(3):e57243. doi: 10.1371/journal.pone.0057243. Epub 2013 Mar 8. PLoS One. 2013. PMID: 23520464 Free PMC article. Clinical Trial.
-
Malignancy Rates in Thyroid Imaging Reporting and Data System Category 3 (TI-RADS 3) Thyroid Nodules: A Retrospective Study.Cureus. 2023 Nov 12;15(11):e48705. doi: 10.7759/cureus.48705. eCollection 2023 Nov. Cureus. 2023. PMID: 38094553 Free PMC article.
-
Role of prophylactic central compartment lymph node dissection in clinically N0 differentiated thyroid cancer patients: analysis of risk factors and review of modern trends.World J Surg Oncol. 2016 May 17;14:149. doi: 10.1186/s12957-016-0879-4. World J Surg Oncol. 2016. PMID: 27185169 Free PMC article. Review.
-
Predictive factors for non-small-volume central lymph node metastases (more than 5 or ≥ 2 mm) in clinically node-negative papillary thyroid carcinoma.Medicine (Baltimore). 2019 Jan;98(1):e14028. doi: 10.1097/MD.0000000000014028. Medicine (Baltimore). 2019. PMID: 30608456 Free PMC article.
-
PES1 promotes the occurrence and development of papillary thyroid cancer by upregulating the ERα/ERβ protein ratio.Sci Rep. 2019 Jan 31;9(1):1032. doi: 10.1038/s41598-018-37648-7. Sci Rep. 2019. PMID: 30705367 Free PMC article.
References
Bibliography
-
- Cerfolio RJ, Bryant AS, Scott E, et al. Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. Chest. 2006;130:1796–1802. - PubMed
-
- Naugler WE, Sakurai T, Kim S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007;317:121–124. - PubMed
-
- Ortega J, Sala C, Flor B, Lledo S. Efficacy and cost–effectiveness of the UltraCision harmonic scalpel in thyroid surgery: an analysis of 200 cases in a randomized trial. J. Laparoendosc. Adv. Surg. Tech. A. 2004;14:9–12. - PubMed
Website
-
- National Cancer Institute: Surveillance, Epidemiology and End Results (SEER) Program. www.seer.cancer.gov.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials